Eton Pharmaceuticals Expands Rare Disease Portfolio with IMPAVIDO® Commercialization Rights
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals has acquired U.S. commercialization rights for IMPAVIDO®, an FDA-approved Orphan Drug for leishmaniasis, further expanding its rare disease product portfolio.
Key Events · Product Development and Regulatory · ETON
-
Acquisition of Commercialization Rights
Eton Pharmaceuticals entered into a supply and distribution agreement for the exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine) oral capsules, an FDA-approved Orphan Drug for leishmaniasis.
-
Financial Terms Detailed
The agreement includes $4.25 million in fixed fees paid through March 2032, up to $4.0 million in sales-based milestone payments, and a revenue split of 55% of net sales up to $7.0 million annually, and 50% above that threshold.
-
Strategic Portfolio Expansion
This transaction further expands Eton's growing portfolio of orphan therapies, aligning with the company's focus on specialized patient populations and building on recent product launches and acquisitions.
-
Established Product with Existing Sales
IMPAVIDO® recorded U.S. sales of $8.1 million in 2025, providing an immediate revenue stream for Eton when its exclusive commercialization rights begin on September 26, 2026.
Analysis · ETON · Life Sciences
Eton Pharmaceuticals is strategically expanding its rare disease portfolio by securing U.S. commercialization rights for IMPAVIDO®, an FDA-approved Orphan Drug with established sales. This move builds on the company's recent positive momentum, including new product approvals and strong financial performance, and is expected to contribute to future revenue growth in a specialized market segment. This agreement comes as the stock trades near its 52-week high, reinforcing positive investor sentiment.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $33.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.9M. The 52-week trading range was $13.09 to $33.41. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.